
Commentary|Articles|December 11, 2014
Pembrolizumab for TNBC
Author(s)Sara A. Hurvitz, MD
Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses the results of a study looking at pembrolizumab (Keytruda) in patients with triple-negative breast cancer (TNBC).
Advertisement
Clinical Pearls
Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses the results of a study looking at pembrolizumab (Keytruda) in patients with triple-negative breast cancer (TNBC).
- Inhibiting the PD-1 pathway showed activity in advanced TNBC in a previous phase I study.
- In this study, a heavily pretreated population of patients with TNBC tolerated pembrolizumab well. Durable responses were observed.
- There remains a need for breast cancer doctors to understand how to manage toxicities associated with immunotherapies.
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Gut Health & Myeloma: How Bacteria May Predict Transplant Success With Pooja Phull, MD
5










































